Dec 11 (Reuters) - Eli Lilly said on Thursday its ‌next-generation ​obesity drug helped patients lose ‌an average of 28.7% of ...

This comes just under a month after Pfizer finalised a deal to acquire Metsera following a bidding war with Novo Nordisk.

Important state and national stories, market and business news, sports and entertainment, delivered in quick-hit fashion ...

Market sentiment has visibly soured. Year-to-date, the share price is down approximately 52%, and it has declined nearly 60% over a twelve-month period. The stock is trading close to its 52-week low, ...

The obesity treatment space has been generating plenty of headlines – and sales – over the past few years. GLP-1 receptor ...

The market for GLP-1 drugs is projected to reach $180 billion in 2034, according to Morningstar Equity Research. Current ...

The coming year, 2026, is shaping up as a critical operational and financial test. A head-to-head comparative study between Novo Nordisk's CagriSema and Eli Lilly's Zepbound, scheduled for 2026, will ...

Pharmacy benefit managers (PBMs) significantly impact GTN revenue through rebates, but patient access issues persist due to ...

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The ...

Eli Lilly said it has lowered the price of single-dose vials of its popular obesity drug Zepbound to make the treatment more ...

Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse. A more ...

Seeking Alpha's roundup of statements, announcements, and remarks that could impact markets, sectors, or individual stocks. President Trump said he has decided on who he plans to nominate to replace ...